{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:35:06Z","timestamp":1784230506384,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clml.2025.05.020","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T16:20:56Z","timestamp":1748622056000},"page":"e924-e932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Meeting Report From the 2024 Symposium on IRAK4 in Cancer: Highlights and Clinical Updates"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4515-8245","authenticated-orcid":false,"given":"Eric S.","family":"Winer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian-Huat","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bently","family":"Doonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus H.","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"von Roemeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.clml.2025.05.020_bib0001","doi-asserted-by":"crossref","first-page":"25404","DOI":"10.1074\/jbc.M109.022392","article-title":"An oligomeric signaling platform formed by the toll-like receptor signal transducers MyD88 and IRAK-4","volume":"284","author":"Motshwene","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2025.05.020_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/frhem.2024.1339870","article-title":"Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer","volume":"3","author":"Garcia-Manero","year":"2024","journal-title":"Front Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.05.020_bib0003","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.20061825","article-title":"A critical role for IRAK4 kinase activity in toll-like receptor-mediated innate immunity","volume":"204","author":"Kim","year":"2007","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.clml.2025.05.020_bib0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","article-title":"IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies","volume":"29","author":"Bennett","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2025.05.020_bib0005","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78136","article-title":"Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations","volume":"11","author":"Choudhary","year":"2022","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.clml.2025.05.020_bib0006","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/cancers14020281","article-title":"Recurrent spliceosome mutations in cancer: mechanisms and consequences of aberrant splice site selection","volume":"14","author":"Ni\u00f1o","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.clml.2025.05.020_bib0007","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/cancers13061232","article-title":"Chromatin-spliceosome mutations in acute myeloid leukemia","volume":"13","author":"Ochi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2025.05.020_bib0008","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/JLB.6AB0520-318RR","article-title":"MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells","volume":"110","author":"Pollyea","year":"2021","journal-title":"J Leukoc Biol"},{"issue":"5","key":"10.1016\/j.clml.2025.05.020_bib0009","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","article-title":"U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies","volume":"21","author":"Smith","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.clml.2025.05.020_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1239082","article-title":"IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies","volume":"14","author":"Parrondo","year":"2023","journal-title":"Front Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2025.05.020_bib0011","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2024-206096","article-title":"R289, a dual IRAK 1\/4 inhibitor, in patients with relapsed\/refractory (R\/R) lower-risk myelodysplastic syndrome (LR-MDS): initial results from a phase 1b study","volume":"144","author":"Garcia-Manero","year":"2024","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2025.05.020_bib0012","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/annrheumdis-2020-eular.3370","article-title":"FRI0016 R835, a novel IRAK1\/4 dual inhibitor in clinical development, blocks toll-like receptor 4 (TLR4) signaling in human and mouse","volume":"79","author":"Lamagna","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2025.05.020_bib0013","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/annrheumdis-2020-eular.4590","article-title":"THU0219 First-in-human study of safety, pharmacokinetics, and pharmacodynamics of IRAK1\/4 inhibitor R835 in healthy subjects","volume":"79","author":"Yan","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.clml.2025.05.020_bib0014","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1021\/acsmedchemlett.0c00255","article-title":"Discovery of CA-4948, an orally bioavailable IRAK4 inhibitor for treatment of hematologic malignancies","volume":"11","author":"Gummadi","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2025.05.020_bib0015","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/01.HS9.0000562260.56570.c7","article-title":"CA-4948, an IRAK4\/FLT3 inhibitor, shows antileukemic activity in mouse models of FLT3 wild-type and FLT3 mutated acute myeloid leukemia (AML)","volume":"3","author":"Booher","year":"2019","journal-title":"Hemasphere"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.05.020_bib0016","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.HS9.0000843408.31385.3f","article-title":"S129: TakeAim Leukemia - a phase 1\/2a study of the IRAK4 inhibitor emavusertib (CA-4948) as monotherapy or in combination with azacitidine or venetoclax in relapsed\/refractory AML or MDS","volume":"6","author":"Garcia-Manero","year":"2022","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.clml.2025.05.020_bib0017","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-22-1682","article-title":"Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases","volume":"29","author":"Von Roemeling","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clml.2025.05.020_bib0018","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.3390\/cancers12082106","article-title":"The DYRK family of kinases in cancer: molecular functions and therapeutic opportunities","volume":"12","author":"Boni","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.clml.2025.05.020_bib0019","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.05.020_bib0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41392-023-01409-4","article-title":"Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases","volume":"8","author":"Song","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.clml.2025.05.020_bib0021","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"issue":"508","key":"10.1016\/j.clml.2025.05.020_bib0022","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8828","article-title":"Overcoming adaptive therapy resistance in AML by targeting immune response pathways","volume":"11","author":"Melgar","year":"2019","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.clml.2025.05.020_bib0023","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.05.020_bib0024","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.05.020_bib0025","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"10.1016\/j.clml.2025.05.020_bib0026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.clml.2025.05.020_bib0027","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.05.020_bib0028","series-title":"IRAK4 inhibitor CA-4948 Potentiates Antitumor Effects of Azacitidine and Venetoclax in human Acute Myeloid Leukemia","first-page":"EP390","author":"Ugolkov","year":"2021"},{"issue":"8","key":"10.1016\/j.clml.2025.05.020_bib0029","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1038\/s41375-021-01265-7","article-title":"Current challenges and unmet medical needs in myelodysplastic syndromes","volume":"35","author":"Platzbecker","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.05.020_bib0030","unstructured":"ClinicalTrials.gov. Dose escalation\/expansion study of CA-4948 as monotherapy in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Available at: https:\/\/clinicaltrials.gov\/study\/NCT04278768. Accessed: January 15, 2025."},{"issue":"5","key":"10.1016\/j.clml.2025.05.020_bib0031","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.05.020_bib0032","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2025.05.020_bib0033","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2025.05.020_bib0034","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3390\/ijms19103198","article-title":"Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance","volume":"19","author":"Staudt","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2025.05.020_bib0035","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1182\/blood-2023-190125","article-title":"Trial in progress: a phase 1b single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in acute myeloid leukemia patients in complete response with measurable residual disease","volume":"142","author":"Burguera","year":"2023","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2025.05.020_bib0036","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2024-208292","article-title":"Preliminary safety, efficacy and molecular characterization in patients with higher-risk myelodysplastic syndrome treated with single agent emavusertib (CA-4948)","volume":"144","author":"Garcia-Manero","year":"2024","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.clml.2025.05.020_bib0037","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2024-207953","article-title":"Preliminary safety, efficacy, and molecular characterization of emavusertib (CA-4948) in relapsed\/refractory acute myeloid leukemia patients","volume":"144","author":"Winer","year":"2024","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.05.020_bib0038","first-page":"919","article-title":"Preliminary efficacy and molecular characterization of relapsed\/refractory acute myeloid leukemia patients with FLT3 mutation with single agent emavusertib (CA-4948)","volume":"8","author":"Winer","year":"2024","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.clml.2025.05.020_bib0039","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nri3190","article-title":"Integration of B cell responses through toll-like receptors and antigen receptors","volume":"12","author":"Rawlings","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.clml.2025.05.020_bib0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/jcm12020399","article-title":"Targeting IRAK4 with emavusertib in lymphoma models with secondary resistance to PI3K and BTK inhibitors","volume":"12","author":"Guidetti","year":"2023","journal-title":"J Clin Med"},{"issue":"12_Suppl","key":"10.1016\/j.clml.2025.05.020_bib0041","doi-asserted-by":"crossref","first-page":"C139","DOI":"10.1158\/1535-7163.TARG-23-C139","article-title":"Abstract C139: the IRAK4 inhibitor emavusertib (CA-4948) synergizes with second generation BTK inhibitors acalabrutinib and zanubrutinib in MYD88-L265P mutated lymphoma cell lines","volume":"22","author":"Guidetti","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.clml.2025.05.020_bib0042","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/10428194.2024.2342560","article-title":"Targets and treatments in primary CNS lymphoma","volume":"65","author":"von Roemeling","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.clml.2025.05.020_bib0043","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.clml.2025.05.020_bib0044","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3390\/cancers14040985","article-title":"Current limitations and novel perspectives in pancreatic cancer treatment","volume":"14","author":"Robatel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clml.2025.05.020_bib0045","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1053\/j.gastro.2022.02.035","article-title":"IRAK4 signaling drives resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma","volume":"162","author":"Somani","year":"2022","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.clml.2025.05.020_bib0046","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130867","article-title":"IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer","volume":"4","author":"Li","year":"2019","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.clml.2025.05.020_bib0047","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/1078-0432.CCR-16-1121","article-title":"Constitutive IRAK4 activation underlies poor prognosis and chemoresistance in pancreatic ductal adenocarcinoma","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.05.020_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104227","article-title":"Which is the best treatment for melanoma brain metastases? A bayesian network meta-analysis and systematic review","volume":"194","author":"Li","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.clml.2025.05.020_bib0049","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.7150\/jca.93306","article-title":"Immunotherapeutic strategies for intra-cranial metastatic melanoma - a meta-analysis and systematic review","volume":"15","author":"Tang","year":"2024","journal-title":"J Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.clml.2025.05.020_bib0050","first-page":"v43","article-title":"Emergent immunotherapy approaches for brain metastases","volume":"3","author":"Wang","year":"2021","journal-title":"Neurooncol Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502500196X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502500196X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:39:31Z","timestamp":1776397171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502500196X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S215226502500196X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.020","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meeting Report From the 2024 Symposium on IRAK4 in Cancer: Highlights and Clinical Updates","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}